Massachusetts General Hospital
Exciting Data in the Treatment of HER2-low from SABCS 2023
March 28th 2024Laura Spring, MD, and Manali Bhave, MD, highlight promising new systemic treatment options on the horizon for patients with metastatic breast cancer, including T-DM1 for HER2-low disease, the AKT inhibitor capivasertib, and novel endocrine therapies.
Read More
Sequencing Antibody-Drug Conjugates (ADCs) in HR+/HER2-Low Metastatic Breast Cancer
March 28th 2024Laura Spring, MD, and Manali Bhave, MD, discuss sequencing approved antibody-drug conjugates, T-DM1 and sacituzumab govitecan, for hormone receptor-positive, HER2-low metastatic breast cancer after progression on chemotherapy.
Read More
Factors for Consideration When Choosing Among Options for Patients with ET-resistant ER+/HER2- mBC
March 21st 2024Oncologists discuss considerations for systemic therapy selection beyond first-line endocrine-based regimens in recurrent hormone receptor-positive, HER2-low metastatic breast cancer, including use of additional endocrine therapy combinations, chemotherapy, and supportive care approaches.
Read More
Approaches to Mutation Testing for Patients With HR+/HER2-low mBC and ET-Resistant Disease
March 21st 2024Laura Spring, MD, and Manali Bhave, MD, discuss considerations for systemic therapy selection in a patient with recurrent hormone receptor-positive, HER2-low breast cancer, including use of plasma and tissue genomic testing and endocrine therapy sequencing based on factors like prior response and ESR1 mutation status.
Read More
Sequencing Therapies in the Third-Line and Beyond for Patients With HER2+ Metastatic Breast Cancer
March 14th 2024Doctors Laura Spring and Manali Bhave discuss summarize their recommended sequence of systemic therapy options for HER2-positive metastatic breast cancer, from first-line taxane and dual HER2 blockade through later lines with T-DM1, tucatinib, and other regimens.
Read More
Standard of Care Regimens for Second-Line Treatment of HER2+ Metastatic Breast Cancer
March 7th 2024Laura Spring, MD, and Manali Bhave, MD, discuss findings from the DESTINY-Breast03 trial and how these results have led them to adopt T-DM1 as the new standard of care over lapatinib/capecitabine for second-line treatment of HER2-positive metastatic breast cancer after progression on first-line trastuzumab and a taxane.
Read More
Key Clinical Trials in the First-Line Treatment of HER2+ Metastatic Breast Cancer
March 7th 2024Oncologists discuss key learnings from clinical trials investigating the first-line treatment of patients with HER2-positive metastatic breast cancer, and how these findings help inform their clinical practice regarding selection of optimal systemic therapy regimens.
Read More
Current First-Line Systemic Therapy Options for HER2+ Metastatic Breast Cancer
February 29th 2024Experts discuss considerations around first-line treatment selection for HER2-positive metastatic breast cancer, including when to diverge from the standard-of-care treatment, as well as the role of brain MRIs at diagnosis.
Read More
Clinical Scenario: A 57-Year-Old Woman With Metastatic Breast Cancer
February 29th 2024Two oncologists present the clinical scenario of a 57-year-old woman with metastatic HER2-positive breast cancer to discuss their approach for incorporating recent research into clinical decision making around systemic therapy.
Read More
Dr. Spring on the Association Between pCR and Neoadjuvant Chemotherapy
December 7th 2018Laura Spring, MD, medical oncologist at Massachusetts General Hospital Cancer Center and instructor in medicine at Harvard Medical School, discusses the association between pathologic complete response (pCR) and neoadjuvant chemotherapy in patients with breast cancer at the 2018 San Antonio Breast Cancer Symposium.
Read More